Oral Proteins & Peptides Market worth $20.36 billion by 2029
The report "Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast to 2029", is projected to reach USD 20.36 billion by 2029 from USD 7.38 billion in 2024, at a CAGR of 22.5% during the forecast period of 2024 to 2029. Some factors contributing to the growth of the global market include rising Prevalence of Chronic Diseases such as diabetes, gastroenterology diseases and kidney diseases, patient preference and compliance for oral route of drug administration and increasing adoption of inorganic growth strategies such as collaboration and partnership for research and development. Notwithstanding this, hurdles in formulation and stability, and stringent regulatory approval process are projected to impede market development.
Browse 407 market data Tables and 53 Figures spread through 318 Pages and in-depth TOC on "Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/oral-proteins-peptides-market-194705708.html
The semaglutide segment accounted for the largest share of the molecule segment in the oral proteins and peptides market in 2023.
Based on molecule, the oral proteins and peptides market is segmented into trofinetide, semaglutide, linaclotide, voclosporin, plecanatide, calcitonin and others. Semaglutide segment dominated the market in 2023 and are expected to dominate the market in the forecast period. High growth of this segment due to several factors such as increasing prevalence of diabetes and rising demand for oral proteins and peptides due to their advantages such as ease of you and high patient compliance. Semaglutide is an analog of glucagon-like peptide-1 (GLP-1), a hormone involved in regulating blood sugar levels and appetite. It is used for the management of type-2 diabetes.
The tables segment is estimated to register the highest growth rate during the forecast period among formulation segment in the oral proteins and peptides market in 2023.
Based on formulation, the oral proteins and peptides market is further segmented into tablet, capsules and oral solution. The tablet segment is estimated to register the highest growth rate during the forecast period. The key factors driving the segment growth include the advantages offer by tablet such as precise dosing of drug, tablets are stable than capsules and have a longer shelf life, ease of use and affordability. Furthermore, these formulations enable controlled release, enhancing bioavailability and ensuring consistent therapeutic effects. Tablets are also cost-effective to manufacture and distribute, allowing for wider accessibility and scalability in commercial production.
Europe the second-largest region in the oral proteins and peptides market.
Based on the region, the oral proteins and peptides market is segmented into six major regions: North America, Europe, Asia Pacific, Latin America, Middle East and Africa. The European market for oral proteins and peptides is the second-largest market globally. The share of this market can be attributed to several key factors. Some of the factors include the strong presence of key market players offering oral proteins and peptides, favorable regulatory scenario and availability of majority of oral proteins and peptides in the region with reimbursement offered in several countries.
Key players in the oral proteins and peptides market include Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), Acadia Pharmaceuticals Inc (US), Aurinia Pharmaceuticals Inc. (Canada), Bausch Health Companies Inc (Canada), CHIESI Farmaceutici S.p.A. (Italy), EnteraBio LTD. (Israel), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), R-Pharm JSC (Russia), Proxima Concepts (US), SWK Holdings Corporation (US), AstraZeneca (UK), Regor Therapeutics Group (China), Viking Therapeutics (US), Protagonist Therapeutics Inc. (US), Rani Therapeutics Holdings, Inc. (US), Carmot Therapeutics, Inc. (US), Terns Pharmaceuticals, Inc. (US), Structure Therapeutics (US), Zealand Pharma (Denmark), Sciwind Biosciences (China), and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China)
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Oral Proteins & Peptides Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
